Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Common Equity (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Common Equity readings, the most recent being $19.5 million for Q4 2017.

  • On a quarterly basis, Common Equity rose 819.91% to $19.5 million in Q4 2017 year-over-year; TTM through Dec 2017 was $19.5 million, a 819.91% increase, with the full-year FY2017 number at $19.5 million, up 819.91% from a year prior.
  • Common Equity hit $19.5 million in Q4 2017 for Eledon Pharmaceuticals, down from $20.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $103.5 million in Q4 2014 to a low of -$55.3 million in Q4 2013.
  • Median Common Equity over the past 5 years was $30.3 million (2016), compared with a mean of $40.2 million.
  • Biggest five-year swings in Common Equity: plummeted 197.12% in 2016 and later surged 819.91% in 2017.
  • Eledon Pharmaceuticals' Common Equity stood at -$55.3 million in 2013, then surged by 287.27% to $103.5 million in 2014, then crashed by 97.31% to $2.8 million in 2015, then plummeted by 197.12% to -$2.7 million in 2016, then surged by 819.91% to $19.5 million in 2017.
  • The last three reported values for Common Equity were $19.5 million (Q4 2017), $20.6 million (Q3 2017), and $23.4 million (Q2 2017) per Business Quant data.